ReNeuron is a UK-based stem cell research company whose shares were listed on the Alternative Investment Market, until it delisted in August 2024 after entering administration[1]. Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.
| Company type | Public company |
|---|---|
| LSE: RENE | |
| Industry | Stem cell research & development |
| Founded | 1997 |
| Headquarters | Surrey, England, UK |
Key people | chairman = Trevor Jones |
| Website | reneuron.com |
As of 2010 ReNeuron was testing the effects of neural stem cells on spinal cords for neuroregeneration.[2] They were also testing the use of fetal stem cells on stroke patients.[3]
References
edit- ^ Life sciences firm ReNeuron to delist as it aims to exit administration - MSN, 30 August 2024
- ^ Cookson, Clive (4 May 2010). "Regenerative medicine: Possibilities multiply for nerve cell regrowth". Retrieved 23 May 2010.
- ^ "EU agency prepares to assess first stem cell drug". Reuters. 12 May 2010. Retrieved 23 May 2010.
External links
edit
 | This article about a company of the UK is a stub. You can help Wikipedia by expanding it. |